Application Notes

Cellastim S – Reconstitution Application Note

Exbumin – Stabilizing Virus with Albumin to Improve Yield Application Note

Lentivirus Production Protocol in Serum-Free Conditions – How To Improve Transfection Efficiency and Titer Yield

OptiVERO – Expansion of VERO Cells Without Serum in Chemically Defined Cell Culture Media

T Cell Cryopreservation Using Exbumin®, Recombinant Human Serum Albumin, and Reduced DMSO

Blog

Evolving Challenges in Closed-System Biomanufacturing

Explore the Latest Developments in T-reg Research and Clinical Application

High-Performance Production of Viral Vectors for Cell and Gene Therapy Using OptiPEAK HEK293t Complete Media

Scaling Innovation: How DiscGenics and InVitria are Leading the Future of Cell Therapy

Posters

Adherent HEK293t Cells Cultured in Pall’s iCELLis® Bioreactor with OptiPEAK HEK293t Blood-Free Chemically Defined Media Exhibit Robust and Rapid Population Doubling Times

Exbumin®, an EMA and FDA Approved Excipient, Provides Improved Performance and Stability in Vaccine Development and Final Formulations

Virus Yield Improvement for Downstream Processing: Exbumin®, Excipient Recombinant Albumin

Product Brochures

ITSE AF – Brochure

Optiferrin – Product Brochure

Product Specifications

ITS – Specifications

SDS

ITSE AF – Safety Data Sheet

Use Guidelines

Cellastim S – Guidelines for Use

ITS – Guidelines for Use

ITSE AF – Guidelines for Use

ITSE+A – Guidelines for Use

Optiferrin – Guidelines for Use

Webinar

Accelerating Vaccine Development Through Use of Blood-Free Components

White Papers

Emergence of Blood-Free Recombinant Human Albumin

Process Optimization for Lentivirus Production in the iCELLis® Nano Using a Chemically Defined, Animal Component Free HEK293 Media